ClinicaliQ Trial Snapshot
- A Study of Acalabrutinib vs Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Active Not Recruiting • Phase III • NCT02970318.
- Acalabrutinib compared to chemotherapy plus antibody therapy for previously treated blood cancer patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL). Conditions: Chronic Lymphocytic Leukemia Interventions: Acalabrutinib (ACP-196), Rituximab, Idelalisib, Bendamustine Lead Sponsor: Acerta Pharma BV Planned Enrollment: 310 participants